Advertisement
Canada markets close in 3 hours 49 minutes

  • S&P/TSX

    21,818.04
    -55.68 (-0.25%)
     

  • S&P 500

    5,015.78
    -55.85 (-1.10%)
     

  • DOW

    37,884.97
    -575.95 (-1.50%)
     

  • CAD/USD

    0.7302
    +0.0004 (+0.06%)
     

  • CRUDE OIL

    82.52
    -0.29 (-0.35%)
     

  • Bitcoin CAD

    87,827.03
    -957.66 (-1.08%)
     

  • CMC Crypto 200

    1,387.46
    +4.89 (+0.35%)
     

  • GOLD FUTURES

    2,341.20
    +2.80 (+0.12%)
     

  • RUSSELL 2000

    1,966.68
    -28.75 (-1.44%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ

    15,471.78
    -240.97 (-1.53%)
     

  • VOLATILITY

    16.69
    +0.72 (+4.51%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6810
    -0.0009 (-0.13%)
     
MARKETS LIVE BLOG:

STOCKS SLIDE AFTER META'S REALITY CHECK, WITH GDP ON DECK

Owner of Facebook and Instagram plans to spend up to US$10B on AI infrastructure investments

Why Investors Should Like BioNTech's Latest Deal With Gilead

Keith Speights, The Motley Fool
·4 min read

BioNTech (NASDAQ: BNTX) has begun to spend some of the cash generated by its COVID-19 vaccine. The German drugmaker recently announced an agreement with Gilead Sciences (NASDAQ: GILD) to acquire a research program and a manufacturing site. In this Motley Fool Live video recorded on July 21, 2021, healthcare and cannabis bureau editor-analyst Olivia Zitkus and Motley Fool contributor Keith Speights discuss what investors should like about BioNTech's deal with Gilead.

Continue reading